Dive Brief:
- Imagion Biosystems has received FDA’s breakthrough device designation for its imaging system in development to detect HER2 metastatic breast cancer.
- The diagnostic system, called MagSense, involves an instrument designed to detect and measure magnetic nanoparticles that are injected into the body to find specific tumor phenotypes and attach to the cancer cells.
- The Melbourne, Australia-based company said it is currently discussing plans with FDA and looking at clinical study sites to begin a first-in-human trial of the MagSense HER2 test.
Dive Insight:
Imagion Biosystems is working to differentiate itself in cancer detection with a system that aims to minimize the need for surgical or biopsy procedures to obtain tissue for pathological assessment. It says the technology as an alternative to MRI, PET, CT and X-ray for faster detection and treatment than conventional imaging methods, according to a presentation to investors.
MD Anderson Cancer Center has been a principal collaborator since 2014 on the company’s magnetic relaxometry technology in a dedicated laboratory in the hospital’s department of imaging physics. In the department, researchers helped to validate biological models, improve computational algorithms and create new nanoparticle chemistries, Imagion said. In 2018, MD Anderson agreed to convert a portion of its research fees into Imagion shares.
Whereas conventional imaging methods cannot distinguish benign from malignant lesions, Imagion’s disease-targeting nanoparticles locate tumors and other specific cells by their molecular signature, according to the company.
The solution of magnetic nanoparticles is injected into the body, where it circulates to find the tumor. Antibodies on the nanoparticles cause them to stick to the tumor being targeted, and the detector, placed over the body, finds and measures the particles.
Imagion claims its nanoparticle formulation has a low-risk safety profile that uses known materials and methods. Further, the detection instrument uses technologies that have been employed in other clinical devices, and its magnetic coils generate field strength orders of a magnitude that is weaker than an MRI, the company said. No special shielding is required in the operating environment.
The nanoparticles are injected in a non-toxic low-dose solution that is biologically safe without exposing patients to radioactivity, which occurs with PET scans, or ionizing radiation, as occurs with X-rays and CT scans, Imagion said. In May, the company announced the completion of a toxicology safety study that showed no observable adverse effects.
The company contends its system is less expensive because the technology uses a small array of sensors for localized detection, unlike more expensive imaging machines that require strong magnetic fields, full body scanning and special facility engineering to provide environmental shielding.
Imagion is also developing applications for its technology in invasive breast cancer, ovarian and prostate cancers, and magnetic hyperthermia, and as a potential MRI contrast agent. In April 2018, the company announced the relocation of its U.S. business operations to San Diego, California, to prepare for clinical testing of the MagSense technology.
